Shibeshih Mitiku Belachew

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9084714/publications.pdf

Version: 2024-02-01

92 papers	10,193 citations	81743 39 h-index	43802 91 g-index
98 all docs	98 docs citations	98 times ranked	10172 citing authors

#	Article	IF	Citations
1	Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2012, 367, 1098-1107.	13.9	1,493
2	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 209-220.	13.9	1,324
3	Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 221-234.	13.9	1,322
4	Elongator Controls the Migration and Differentiation of Cortical Neurons through Acetylation of Î±-Tubulin. Cell, 2009, 136, 551-564.	13.5	688
5	Postnatal NG2 proteoglycanâ€“expressing progenitor cells are intrinsically multipotent and generate functional neurons. Journal of Cell Biology, 2003, 161, 169-186.	2.3	445
6	Antiâ€“JC virus antibody levels in serum or plasma further define risk of natalizumabâ€associated progressive multifocal leukoencephalopathy. Annals of Neurology, 2014, 76, 802-812.	2.8	390
7	Neurotransmitters as early signals for central nervous system development. Cell and Tissue Research, 2001, 305, 187-202.	1.5	335
8	The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. British Journal of Pharmacology, 2002, 136, 659-672.	2.7	292
9	Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurology, 2020, 77, 1132.	4.5	245
10	NG2-expressing cells in the subventricular zone are type Câ€“like cells and contribute to interneuron generation in the postnatal hippocampus. Journal of Cell Biology, 2004, 165, 575-589.	2.3	230
11	Expression of the green fluorescent protein in the oligodendrocyte lineage: A transgenic mouse for developmental and physiological studies. Journal of Neuroscience Research, 2002, 70, 529-545.	1.3	158
12	Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1190-1197.	0.9	156
13	Proliferative generation of mammalian auditory hair cells in culture. Mechanisms of Development, 2002, 112, 79-88.	1.7	144
14	Autocrine/Paracrine Activation of the GABA_AReceptor Inhibits the Proliferation of Neurogenic Polysialylated Neural Cell Adhesion Molecule-Positive (PSA-NCAM⁺) Precursor Cells from Postnatal Striatum. Journal of Neuroscience, 2003, 23, 3278-3294.	1.7	137
15	Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain, 2019, 142, 2787-2799.	3.7	136
16	Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions. Multiple Sclerosis Journal, 2019, 25, 1915-1925.	1.4	122
17	Identification of Sox17 as a Transcription Factor That Regulates Oligodendrocyte Development. Journal of Neuroscience, 2006, 26, 9722-9735.	1.7	121
18	Cell â€œcircadianâ€•cycle: New role for mammalian core clock genes. Cell Cycle, 2009, 8, 832-837.	1.3	110

#	Article	IF	Citations
19	Belgian Fabry Study. Stroke, 2010, 41, 863-868.	1.0	99
20	Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. Multiple Sclerosis and Related Disorders, 2017, 12, 70-78.	0.9	92
21	Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study. Journal of Medical Internet Research, 2019, 21, e14863.	2.1	90
22	Cdk2 is critical for proliferation and self-renewal of neural progenitor cells in the adult subventricular zone. Journal of Cell Biology, 2007, 179, 1231-1245.	2.3	82
23	Five years of ocrelizumab in relapsing multiple sclerosis. Neurology, 2020, 95, e1854-e1867.	1.5	81
24	Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. Multiple Sclerosis Journal, 2018, 24, 963-973.	1.4	79
25	Period 2 regulates neural stem/progenitor cell proliferation in the adult hippocampus. BMC Neuroscience, 2009, 10, 30.	0.8	75
26	MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy: Figure 1. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 224-226.	0.9	74
27	Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsingâ€remitting multiple sclerosis. European Journal of Neurology, 2011, 18, 240-245.	1.7	73
28	Shaker-type potassium channel subunits differentially control oligodendrocyte progenitor proliferation. Glia, 2004, 48, 337-345.	2.5	71
29	Comparison of the Timed 25-Foot and the 100-Meter Walk as Performance Measures in Multiple Sclerosis. Neurorehabilitation and Neural Repair, 2011, 25, 672-679.	1.4	70
30	Cyclin-Dependent Kinase-2 Controls Oligodendrocyte Progenitor Cell Cycle Progression and Is Downregulated in Adult Oligodendrocyte Progenitors. Journal of Neuroscience, 2002, 22, 8553-8562.	1.7	58
31	Comparative efficacy of switching to natalizumab in active multiple sclerosis. Annals of Clinical and Translational Neurology, 2015, 2, 373-387.	1.7	57
32	Cdk6-Dependent Regulation of G1 Length Controls Adult Neurogenesis. Stem Cells, 2011, 29, 713-724.	1.4	54
33	A smartphone sensor-based digital outcome assessment of multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 654-664.	1.4	51
34	Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 1692-1694.	13.9	50
35	Inhibition of cyclinâ€dependent kinases induces differentiation of supernumerary hair cells and Deiters' cells in the developing organ of Corti. FASEB Journal, 2003, 17, 1-26.	0.2	45
36	Motor Fatigue Measurement by Distance-Induced Slow Down of Walking Speed in Multiple Sclerosis. PLoS ONE, 2012, 7, e34744.	1.1	45

#	Article	IF	Citations
37	Functional glycine receptors are expressed by postnatal nestin-positive neural stem/progenitor cells. European Journal of Neuroscience, 2002, 15, 1299-1305.	1.2	44
38	Untangling the Functional Potential of PSA-NCAM-Expressing Cells in CNS Development and Brain Repair Strategies. Current Medicinal Chemistry, 2003, 10, 2185-2196.	1.2	43
39	Glycine triggers an intracellular calcium influx in oligodendrocyte progenitor cells which is mediated by the activation of both the ionotropic glycine receptor and Na+-dependent transporters. European Journal of Neuroscience, 2000, 12, 1924-1930.	1.2	42
40	Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Annals of Neurology, 2018, 84, 527-536.	2.8	42
41	Unraveling Oligodendrocyte Origin and Function by Cell-Specific Transgenesis. Developmental Neuroscience, 2001, 23, 287-298.	1.0	41
42	Peripheral benzodiazepine receptor (PBR) ligand cytotoxicity unrelated to PBR expression. Biochemical Pharmacology, 2005, 69, 819-830.	2.0	41
43	Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial. Multiple Sclerosis Journal, 2018, 24, 1862-1870.	1.4	41
44	Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology, 2019, 93, e1778-e1786.	1.5	37
45	Synaptic and extrasynaptic neurotransmitter receptors in glial precursors' quest for identity. Glia, 2004, 48, 185-196.	2.5	36
46	Comparative efficacy of first-line natalizumab vs IFN-Î² or glatiramer acetate in relapsing MS. Neurology: Clinical Practice, 2016, 6, 102-115.	0.8	33
47	No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731876064.	0.5	32
48	Phenotypical characterization of Î±-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young. Clinical Neurology and Neurosurgery, 2013, 115, 1088-1093.	0.6	31
49	Adult Neurogenesis and the Diseased Brain. Current Medicinal Chemistry, 2009, 16, 652-666.	1.2	30
50	Natalizumab reduces relapse clinical severity and improves relapse recovery in MS. Multiple Sclerosis and Related Disorders, 2014, 3, 705-711.	0.9	30
51	Smartphone-based remote assessment of upper extremity function for multiple sclerosis using the Draw a Shape Test. Physiological Measurement, 2020, 41, 054002.	1.2	29
52	Cultured oligodendrocyte progenitors derived from cerebral cortex express a glycine receptor which is pharmacologically distinct from the neuronal isoform. European Journal of Neuroscience, 1998, 10, 3556-3564.	1.2	28
53	Developmental regulation of neuroligand-induced responses in cultured oligodendroglia. NeuroReport, 1998, 9, 973-980.	0.6	28
54	The earlier, the smaller, the better for natalizumab-associated PML: In MRI vigilance veritas?. Neurology, 2012, 79, 1067-1069.	1.5	28

#	Article	IF	Citations
55	Identification of PSF, the polypyrimidine tract-binding protein-associated splicing factor, as a developmentally regulated neuronal protein. Journal of Neuroscience Research, 1999, 57, 62-73.	1.3	26
56	Diazepam-insensitive GABAA receptors on postnatal spiral ganglion neurones in culture. NeuroReport, 1997, 8, 591-596.	0.6	24
57	CDK2 is Dispensable for Adult Hippocampal Neurogenesis. Cell Cycle, 2007, 6, 3065-3069.	1.3	24
58	TheYin andYang of cell cycle progression and differentiation in the oligodendroglial lineage. Mental Retardation and Developmental Disabilities Research Reviews, 2006, 12, 85-96.	3.5	22
59	Strategies to regenerate hair cells: Identification of progenitors and critical genes. Hearing Research, 2008, 236, 1-10.	0.9	22
60	Î²-Carbolines induce apoptosis in cultured cerebellar granule neurons via the mitochondrial pathway. Neuropharmacology, 2005, 48, 105-117.	2.0	21
61	A corrected version of the Timed-25 Foot Walk Test with a dynamic start to capture the maximum ambulation speed in multiple sclerosis patients. NeuroRehabilitation, 2012, 30, 261-266.	0.5	19
62	Patterning Chronic Active Demyelination in Slowly Expanding/Evolving White Matter MS Lesions. American Journal of Neuroradiology, 2020, 41, 1584-1591.	1.2	19
63	U-turn speed is a valid and reliable smartphone-based measure of multiple sclerosis-related gait and balance impairment. Gait and Posture, 2021, 84, 120-126.	0.6	19
64	Serum Neurofilament Light and Multiple Sclerosis Progression Independent of Acute Inflammation. JAMA Network Open, 2022, 5, e2147588.	2.8	19
65	Primary central nervous system lymphoma in a patient treated with Natalizumab. Annals of Neurology, 2011, 69, 1060-1061.	2.8	17
66	Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. Multiple Sclerosis and Related Disorders, 2018, 24, 11-19.	0.9	17
67	Oligodendrocyte development and myelinogenesis are not impaired by high concentrations of phenylalanine or its metabolites. Journal of Inherited Metabolic Disease, 2010, 33, 113-120.	1.7	16
68	Natalizumab improves ambulation in relapsingâ^'remitting multiple sclerosis: results from the prospective <scp>TIMER</scp> study and a retrospective analysis of <scp>AFFIRM</scp>. European Journal of Neurology, 2015, 22, 570-577.	1.7	16
69	More on JC Viremia in Natalizumab-Treated Patients with Multiple Sclerosis. New England Journal of Medicine, 2013, 369, 1279-1280.	13.9	15
70	Developmental Regulation of Î²-Carboline-Induced Inhibition of Glycine-Evoked Responses Depends on Glycine Receptor Î² Subunit Expression. Molecular Pharmacology, 2005, 67, 1783-1796.	1.0	13
71	Abnormalities in normal-appearing white matter from which multiple sclerosis lesions arise. Brain Communications, 2021, 3, fcab176.	1.5	13
72	Nextâ€generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells. Clinical and Translational Immunology, 2021, 10, e1295.	1.7	13

#	Article	IF	Citations
73	Î²-Carbolines induce apoptotic death of cerebellar granule neurones in culture. NeuroReport, 1996, 7, 3041-3046.	0.6	12
74	ACQUIRED TONSILLAR HERNIATION AND SYRINGOMYELIA AFTER PLEURAL EFFUSION ASPIRATION. Neurosurgery, 2008, 62, E1172-E1173.	0.6	12
75	Exploring the Impact of Fatigue in Progressive Multiple Sclerosis: A Mixed-Methods Analysis. Multiple Sclerosis and Related Disorders, 2020, 43, 102207.	0.9	12
76	Chronic lesion activity and disability progression in secondary progressive multiple sclerosis. BMJ Neurology Open, 2022, 4, e000240.	0.7	12
77	Astroglia-released factor shows similar effects as benzodiazepine inverse agonists. Journal of Neuroscience Research, 1994, 39, 364-376.	1.3	10
78	Natalizumab to kill two birds with one stone. Inflammatory Bowel Diseases, 2011, 17, E62-E63.	0.9	10
79	Slowly expanding lesions are a marker of progressive MS â€“ No. Multiple Sclerosis Journal, 2021, 27, 1681-1683.	1.4	9
80	Chemical inhibitors of cyclinâ€dependent kinases control proliferation, apoptosis and differentiation of oligodendroglial cells. International Journal of Developmental Neuroscience, 2003, 21, 321-326.	0.7	8
81	Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP). PLoS ONE, 2016, 11, e0144834.	1.1	8
82	Striatal PSA-NCAM+ precursor cells from the newborn rat express functional glycine receptors. NeuroReport, 2004, 15, 583-587.	0.6	5
83	061â€…Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis (RMS) (ENCORE). Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A25.2-A25.	0.9	5
84	PO129â€…Neda analysis by epoch in the opera studies of ocrelizumab. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A46.2-A46.	0.9	3
85	Long-term Reduction in Brain MRI Disease Activity and Atrophy after 5 years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2018, 26, 265.	0.9	3
86	033â€…Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis (PPMS) in the oratorio study (ENCORE). Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A14.1-A14.	0.9	3
87	Severe liver dysfunction in a patient with multiple sclerosis: the guilty party is not always the disease-modifying therapy. Multiple Sclerosis Journal, 2009, 15, 1378-1379.	1.4	2
88	Advancing the understanding of progression in multiple sclerosis: an interview with Shibeshih Belachew. Neurodegenerative Disease Management, 2018, 8, 9-12.	1.2	2
89	Astroglia-released factor with negative allosteric modulatory properties at the GABAA receptor. Biochemical Pharmacology, 1996, 52, 465-473.	2.0	1
90	Evaluation of no evidence of progression or active disease (nepad) in patients with primary progressive multiple sclerosis in the oratorio trial. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, e1.85-e1.	0.9	0

#	Article	IF	Citations
91	PO127â€…Composite confirmed disability progression in oratorio. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A45.3-A46.	0.9	0
92	PND18 - PROGRESSION OF DISABILITY IN PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS: A RETROSPECTIVE COHORT STUDY USING DATA FROM THE MSBASE REGISTRY AND A CONTEXTUALISATION WITH AN EXISTING NATURAL HISTORY DATASET. Value in Health, 2018, 21, S332.	0.1	0